Literature DB >> 19712953

Immunological stimulation for the treatment of leishmaniasis: a modality worthy of serious consideration.

Ahmed Mudawi Musa1, Sassan Noazin, E A G Khalil, Farrokh Modabber.   

Abstract

Instead of relying on drugs to reduce the parasite burden of leishmaniasis, and waiting for the effector immune response to develop in time to control the parasites, immunotherapy in conjunction with chemotherapy can rapidly induce the effector immune response. With a safe and potent drug plus an affordable therapeutic vaccine (immunostimulant), which remains to be developed, a single visit by patients with visceral or cutaneous leishmaniasis might be sufficient to induce a quick and lasting recovery. Drug toxicity and the emergence of resistance could also be dramatically reduced compared with present long-term monotherapy. Immunotherapy could be an effective addition to chemotherapy for leishmaniasis.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19712953     DOI： 10.1016/j.trstmh.2009.07.026

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN： 0035-9203            Impact factor:   2.184


  15 in total

1.  Sequential chemoimmunotherapy of experimental visceral leishmaniasis using a single low dose of liposomal amphotericin B and a novel DNA vaccine candidate.

Authors:  Karin Seifert; Christiane Juhls; Francisco J Salguero; Simon L Croft
Journal:  Antimicrob Agents Chemother       Date:  2015-06-08       Impact factor: 5.191

2.  Augmentation of antileishmanial efficacy of miltefosine in combination with tuftsin against experimental visceral leishmaniasis.

Authors:  Nishi Shakya; Shraddha A Sane; Wahajul Haq; Suman Gupta
Journal:  Parasitol Res       Date:  2012-03-06       Impact factor: 2.289

3.  Therapeutic vaccination with recombinant adenovirus reduces splenic parasite burden in experimental visceral leishmaniasis.

Authors:  Asher Maroof; Najmeeyah Brown; Barbara Smith; Michael R Hodgkinson; Alice Maxwell; Florian O Losch; Ulrike Fritz; Peter Walden; Charles N J Lacey; Deborah F Smith; Toni Aebischer; Paul M Kaye
Journal:  J Infect Dis       Date:  2012-02-01       Impact factor: 5.226

Review 4.  Immunotherapy and Immunochemotherapy in Visceral Leishmaniasis: Promising Treatments for this Neglected Disease.

Authors:  Bruno Mendes Roatt; Rodrigo Dian de Oliveira Aguiar-Soares; Wendel Coura-Vital; Henrique Gama Ker; Nádia das Dores Moreira; Juliana Vitoriano-Souza; Rodolfo Cordeiro Giunchetti; Cláudia Martins Carneiro; Alexandre Barbosa Reis
Journal:  Front Immunol       Date:  2014-06-13       Impact factor: 7.561

5.  A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KH.

Authors:  Mohamed Osman; Anoop Mistry; Ada Keding; Rhian Gabe; Elizabeth Cook; Sarah Forrester; Rebecca Wiggins; Stefania Di Marco; Stefano Colloca; Loredana Siani; Riccardo Cortese; Deborah F Smith; Toni Aebischer; Paul M Kaye; Charles J Lacey
Journal:  PLoS Negl Trop Dis       Date:  2017-05-12

6.  Histopathological and immunohistochemical aspects of American cutaneous leishmaniasis before and after different treatments.

Authors:  Agostinho Gonçalves Viana; Wilson Mayrink; Carlos Alberto de Carvalho Fraga; Luciana Maria Silva; Patrícia Luciana Batista Domingos; Paulo Rogério Ferreti Bonan; Alfredo Maurício Batista de Paula; Ana Cristina de Carvalho Botelho
Journal:  An Bras Dermatol       Date:  2013 Jan-Feb       Impact factor: 1.896

7.  Use of a recombinant cysteine proteinase from Leishmania (Leishmania) infantum chagasi for the Immunotherapy of canine visceral Leishmaniasis.

Authors:  Josie Haydée Lima Ferreira; Lucilene Dos Santos Silva; Ieda Maria Longo-Maugéri; Simone Katz; Clara Lúcia Barbiéri
Journal:  PLoS Negl Trop Dis       Date:  2014-03-13

8.  Combination of liposomal CpG oligodeoxynucleotide 2006 and miltefosine induces strong cell-mediated immunity during experimental visceral leishmaniasis.

Authors:  Rahul Shivahare; Preeti Vishwakarma; Naveen Parmar; Pawan Kumar Yadav; Wahajul Haq; Mrigank Srivastava; Suman Gupta; Susanta Kar
Journal:  PLoS One       Date:  2014-04-14       Impact factor: 3.240

9.  Leishmania donovani Nucleoside Hydrolase Terminal Domains in Cross-Protective Immunotherapy Against Leishmania amazonensis Murine Infection.

Authors:  Dirlei Nico; Daniele Crespo Gomes; Iam Palatnik-de-Sousa; Alexandre Morrot; Marcos Palatnik; Clarisa Beatriz Palatnik-de-Sousa
Journal:  Front Immunol       Date:  2014-06-11       Impact factor: 7.561

Review 10.  Immunomodulatory Therapy of Visceral Leishmaniasis in Human Immunodeficiency Virus-Coinfected Patients.

Authors:  Wim Adriaensen; Thomas P C Dorlo; Guido Vanham; Luc Kestens; Paul M Kaye; Johan van Griensven
Journal:  Front Immunol       Date:  2018-01-12       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.